South Korea Hereditary Angioedema (HAE) Therapeutics Market 2023 Share, Size, Key Players, Revenue Analysis | Prudent Markets

The South Korea Hereditary Angioedema (HAE) Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global South Korea Hereditary Angioedema (HAE) Therapeutics market. This report explores all the key factors affecting the growth of the global South Korea Hereditary Angioedema (HAE) Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/141720/

Report Overview

The South Korea Hereditary Angioedema (HAE) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach xx billion by 2028, exhibiting a CAGR of around xx% during the forecast period.

Hereditary angioedema is a disease of congenital deficiency or functional defect in the C1 esterase inhibitor (C1-INH) consequent to mutation in theSERPING1gene, which encodes C1-INH. This disease manifests as recurrent, non-pitting, non-pruritic subcutaneous, or submucosal oedema as well as an erythematous rash in some cases. These symptoms result from the uncontrolled localized production of bradykinin.

The most commonly affected sites are the extremities, face, gastrointestinal tract, and respiratory system. When the respiratory system is affected by hereditary angioedema, swelling of the airway can restrict breathing and lead to life-threatening obstruction. As per the National Organization for Rare Disorders (NORD), the prevalence of hereditary angioedema is 1 per 50,000 to 1 in 150,000 individuals worldwide. The expected number of patients in Korea is about 1,000. However, as of 2019, only 80 patients were diagnosed with hereditary angioedema in Korea.

Market Drivers

Growing cases of hereditary angioedema (HAE) and rising initiatives for improving awareness levels among the general population are factor contributing to the growth of the market. Pharmaceutical drug manufacturers are increasing focus on developing novel therapeutics for hereditary angioedema in order to cater to the large unmet medical needs. Government initiatives and increase in healthcare spending is also fuelling the HAE therapeutics market. For instance, Takeda Pharmaceutical Korea announced that the Ministry of Health and Welfare would grant expanded reimbursement for its acute hereditary angioedema seizure treatment, Firazyr, from March 2021. The ministry will expand the insurance benefits for Firazyr to two doses per patient from the existing one-dose regimen.

Significant number of patients are being misdiagnosed for the condition, also the number of undiagnosed cases it very high which impedes the market growth.

To Know More About COVID-19 Impact On South Korea Hereditary Angioedema (HAE) Therapeutics Market @ https://www.prudentmarkets.com/sample-request/141720/

Market Segmentation

By Drug Class:

According to the drug class, market is segmented into C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, and others.

By Route of Administration:

According to route of administration, HAE therapeutics market segments are intravenous, subcutaneous and others.

Top Players

The hereditary angioedema therapeutics market is highly consolidated in terms of competition and consists of limited major players. Some of the companies which are currently dominating the market are Takeda Pharmaceutical Korea, Pharming Healthcare, BioCryst Pharmaceuticals, Sanofi.

Pharming Group N.V. and their Seoul based South Korean specialty pharma partner Hyupjin have received the marketing authorization for Ruconest in South Korea since 2016. Ruconest was the first approved recombinant C1 esterase inhibitor worldwide.

Launch of Takeda Pharmaceutical Korea's 'Firazyr' has improved the conditions of HAE patients in Korea tremendously. Firazyr is an emergency treatment used for the acute attack of hereditary angioedema over two years of age due to a deficiency of a C1-esterase inhibitor by blocking the vasodilating action of Bradykinin to relieve acute seizures within two hours.

Highlighted Segments of South Korea Hereditary Angioedema (HAE) Therapeutics Market:

Industry Overview: The first section of the research study covers an overview of the global South Korea Hereditary Angioedema (HAE) Therapeutics Market, market status and prospects, and product range. In addition, it provides highlights of the major segments of the global Market, i.e., region, type, and application segments.

Competitive Analysis: This report illuminates important mergers and acquisitions, business expansion, product or service differences, market concentration, the competitive status of the global South Korea Hereditary Angioedema (HAE) Therapeutics Market, and market size by player.

Company Profiles and Key Data: This section covers companies profiling the major players in the global South Korea Hereditary Angioedema (HAE) Therapeutics Market based on the aforementioned revenue, products, business, and other factors.

Market size by type and application: In addition to providing an in-depth analysis of the industry size by type and application, this section provides research on top end users or consumers and potential applications.

Market Dynamics: This report covers the drivers, trends, and opportunities of the global South Korea Hereditary Angioedema (HAE) Therapeutics Market. This section also includes Porter's analysis of five forces.

Findings and Conclusions: It provides strong recommendations for new as well as established players for securing a position of strength in the global South Korea Hereditary Angioedema (HAE) Therapeutics Market.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/141720/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global South Korea Hereditary Angioedema (HAE) Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global South Korea Hereditary Angioedema (HAE) Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the South Korea Hereditary Angioedema (HAE) Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the South Korea Hereditary Angioedema (HAE) Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the South Korea Hereditary Angioedema (HAE) Therapeutics
Chapter 4: Presenting the South Korea Hereditary Angioedema (HAE) Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the South Korea Hereditary Angioedema (HAE) Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Why should you purchase this report?

-Prudent Markets provides the vital historical and analysis data of global South Korea Hereditary Angioedema (HAE) Therapeutics market.
-The report provides the entire assessment of the future market and altering market scenario or behavior.
-All the business decision could be backed through the several strategic business methodologies offered in the report.
-An extra edge in the competitive market could be obtained from this elaborative research report
-The report offers all the competitive landscape, growth drivers, applications, market dynamics, and other necessary details as well.

Purchase this report (Single User License) @ https://www.prudentmarkets.com/checkout/?id=141720&license_type=su

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the South Korea Hereditary Angioedema (HAE) Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.